Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05022030
Other study ID # 20210602
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date July 21, 2021
Est. completion date June 1, 2026

Study information

Verified date March 2024
Source West China Hospital
Contact Xiaofen Li, M.D.
Phone +86-28-85422589
Email lxf0827@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This prospective, randomized, phase 2 study is conducted to evaluate the efficacy and safety of first line mCapOX plus cetuximab versus mFOLFOX6 plus cetuximab for metastatic left-sided CRC patients with wild-type RAS and BRAF genes.


Description:

The patients, who meet the inclusion criteria and have signed the informed consent, will be randomly assigned (1:1 ratio) to receive mCapOX plus cetuximab regimen (arm A) and mFOLFOX6 plus cetuximab regimen (arm B).


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date June 1, 2026
Est. primary completion date June 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Able to provide written informed consent and can understand and comply with the requirements of the study; - Men and women = 18 years of age; - Patients with histologically or cytologically confirmed metastatic left-sided colorectal adenocarcinoma with wild-type RAS and BRAF genes; - Presence of at least one evaluable lesion, as defined in RECIST Version 1.1; - With an Eastern Cooperative Oncology Group (ECOG) performance status of = 1; - No palliative first-line chemotherapy, targeted, immunotherapy, or prior platinum-based adjuvant chemotherapy, relapse more than 12 months from the end of adjuvant chemotherapy; - According to the imaging findings and surgical assessment of initial unresectable, synchronous metastatic colorectal cancer, no serious complications of the primary tumor (obstruction, perforation, massive hemorrhage that cannot be treated in internal medicine, etc.) ; - Life expectancy of longer than 3 months ( clinical assessment); - Requirements for lab indicators neutrophils = 1.5 × 109/L, platelets = 75 × 109/L, hemoglobin = 8 g/dL, total bilirubin = 1.5 × upper limit of normal (UNL); ASAT (SGOT) and/or ALAT (SGPT) = 2.5 × UNL (= 5 × UNL if liver metastases); alkaline phosphatase = 2.5 × UNL (= 5 × UNL if liver metastases, = 10 × UNL if bone metastases); LDH < 1500 U/L; creatinine clearance (calculated according to Cockcroft and Gault formula) > 50 mL/min or serum creatinine = 1.5 × UNL; Exclusion Criteria: - Patients with mCRC who were initially resectable with R0 resection or radiofrequency or SBRT were excluded. - Patients diagnosed with MSI-H or dMMR by PCR or immunohistochemistry - Hypersensitivity to any therapeutic agent. - Patients who received adjuvant chemotherapy containing oxaliplatin and fluorouracil within 12 months before entering the study; - Patients who have failed one or more palliative chemotherapy regimens; - Patients with uncontrolled hepatitis B virus - Peripheral neuropathy = CTC grade 2; - Neurological or psychiatric disorders affecting cognitive performance; - Patients with central nervous system metastasis could not be controlled with radiotherapy; - Previous enteritis, chronic diarrhea, or recurrent bowel obstruction; uncontrolled bleeding from internal medicine; bowel perforation - Uncontrolled concomitant diseases within 6 months before the study, including unstable angina, acute myocardial infarction, cerebrovascular accident, etc.; - Pregnant or lactating patients, or those of childbearing potential who do not take adequate contraceptive measures; - History of other malignancies, but no disease-free survival longer than 5 years; - Patients concurrently receiving other anti-tumor treatment or participating in other interventional clinical trials; - Patients who are unable to comply with this study for psychological, family or social reasons. - Patients with other serious diseases that the investigator considers not suitable.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
mCapOX plus cetuximab
capecitabine 1000mg/m2 po bid d1-7+oxaliplatin ivgtt 85mg/m2 d1+cetuximab ivgtt 500mg/m2, q2w
mFOLFOX6 plus cetuximab
oxaliplatin ivgtt 85mg/m2 d1+ leucovorin ivgtt 400mg/m2 d1+ fluorouracil iv bolus 400mg/m2 d1+ fluorouracil 2400mg/m2 continuous infusion for 46h+cetuximab ivgtt 500mg/m2, q2w

Locations

Country Name City State
China West China Hospital of Sichuan University Chengdu Sichuan

Sponsors (2)

Lead Sponsor Collaborator
West China Hospital First Affiliated Hospital of Chongqing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival (PFS) rate at 9 months PFS rate at 9 months is defined as the proportion of patients without PD or death at 9 months after randomization. 9 months
Secondary Objective response rate The rate of complete response and partial response 6 months
Secondary Disease control rate The rate of complete response, partial response and stable disease. 6 months
Secondary Progression free survival Progression free survival is defined as the period from randomization to disease progress or death. up to 3 years
Secondary Overall survival Overall survial is defined as the period from randomization to death. up to 4 years
Secondary Adverse event rate The rate of adverse event after treatment 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05074966 - The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts Phase 3
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Suspended NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting NCT05056389 - Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA) Phase 1
Completed NCT04551014 - Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm N/A
Completed NCT04551001 - Evaluation of Cold Forcep and Cold Snare Polypectomy for Polyps Less Than or Equal to 3mm in Size During Colonoscopy N/A
Recruiting NCT04270500 - The Impact of Physical Exercise on Sleep in Colorectal Cancer Patients During Prehabilitation Period N/A
Recruiting NCT03667911 - Virtual Reality Videos in Improving Bowel Preparation Quality of Colonoscopy N/A
Not yet recruiting NCT04073680 - A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05572684 - A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Phase 1/Phase 2
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03567850 - Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC N/A
Recruiting NCT05870332 - Nationwide Study of Artificial Intelligence in Adenoma Detection for Colonoscopy
Completed NCT04534218 - Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer Phase 2
Enrolling by invitation NCT05590117 - Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer Early Phase 1
Recruiting NCT03129139 - A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Phase 1
Completed NCT04195646 - Computer Aided Detection of Polyps During Colonoscopy Procedures N/A
Not yet recruiting NCT03618329 - Effect of Prehabilitation on the Lean Mass Index (IMM) in ERAS PROGRAMM. N/A
Not yet recruiting NCT03261752 - New Genes in the Carcinogenesis of Colorectal Cancer
Terminated NCT03621982 - Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Phase 1